P/B
0,1
INmune Bio
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.
$35M
Market Cap • 11/6/2026
2015
(11 years)
Founded
2019
(7 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
—
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
7,7
EPS
—
Market Cap
Market Cap
35M
EV
19,9M
EV/Revenue
0
EV/EBITDA
-1,1
EV/EBIT
-1,1
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-5,7%
Total Yield
-5,7%
Payout
0%
Profitability
Gross Margin
—
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
0%
Capex/Revenue
0%
Capex/D&A
232%
Capex/OCF
-4,4%
SBC/OCF
—
% PPE
10,5%
% Goodwill
0%
ROE
—
ROIC
1428,5%
Growth
CAGR Revenue 5Y
-100%
CAGR Op. Income 5Y
-5,3%
CAGR Net Income 5Y
-6,7%
CAGR EPS 5Y
-17,3%
CAGR OCF 5Y
-9,4%
Leverage
N.D./EBITDA
0,9
Debt/Equity
0%
Current Ratio
6,4
Quick Ratio
6,2
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!